Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis

This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental dermatology 2024-02, Vol.49 (3), p.272-273
Main Authors: Abbad-Jaime de Aragón, Carlota, Berna-Rico, Emilio, Goas, Almudena, Pérez-Bootello, Javier, Ballester-Martinez, María Asunción, Jaén, Pedro, Blauvelt, Andrew, González-Cantero, Álvaro
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Humans
Induction Chemotherapy
Psoriasis - drug therapy
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c247t-536e69cf260c1f5037169a7880efbd9c65b8b1ac215aa25c53af4eb012841cd33
container_end_page 273
container_issue 3
container_start_page 272
container_title Clinical and experimental dermatology
container_volume 49
creator Abbad-Jaime de Aragón, Carlota
Berna-Rico, Emilio
Goas, Almudena
Pérez-Bootello, Javier
Ballester-Martinez, María Asunción
Jaén, Pedro
Blauvelt, Andrew
González-Cantero, Álvaro
description This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of < 1.
doi_str_mv 10.1093/ced/llad361
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2882324079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2882324079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c247t-536e69cf260c1f5037169a7880efbd9c65b8b1ac215aa25c53af4eb012841cd33</originalsourceid><addsrcrecordid>eNo1kMtKxDAUQIMoOo6u3EuWgsTJo3l0KeILBtyM65ImqRNtm9qkDOPX-C1-mRFnVpd7OfcsDgAXBN8QXLKFcXbRttoyQQ7AjDDBEaUMH4IZZlgiUTJ1Ak5jfMeYMCL5MThhUknFZTEDfuVbO-oP_zV1uka-t5NJPvQwrd2ohy1sQtuGjbOw3v5864h652zebIi-f4O-h4NO3vUpwo1Pa9hlHUoBdcHm_-TgEMPodfTxDBw1uo3ufDfn4PXhfnX3hJYvj893t0tkaCET4kw4UZqGCmxIwzGTRJRaKoVdU9vSCF6rmmhDCdeacsOZbgpXY0JVQYxlbA6u_r3DGD4nF1PV-WhcLtS7MMWKKkUZLbAsM3r9j5oxxDi6phpG3-lxWxFc_bWtcttq1zbTlzvxVHf5vmf3Mdkvrnx45Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2882324079</pqid></control><display><type>article</type><title>Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis</title><source>Oxford Journals Online</source><creator>Abbad-Jaime de Aragón, Carlota ; Berna-Rico, Emilio ; Goas, Almudena ; Pérez-Bootello, Javier ; Ballester-Martinez, María Asunción ; Jaén, Pedro ; Blauvelt, Andrew ; González-Cantero, Álvaro</creator><creatorcontrib>Abbad-Jaime de Aragón, Carlota ; Berna-Rico, Emilio ; Goas, Almudena ; Pérez-Bootello, Javier ; Ballester-Martinez, María Asunción ; Jaén, Pedro ; Blauvelt, Andrew ; González-Cantero, Álvaro</creatorcontrib><description>This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of &lt; 1.</description><identifier>ISSN: 0307-6938</identifier><identifier>EISSN: 1365-2230</identifier><identifier>DOI: 10.1093/ced/llad361</identifier><identifier>PMID: 37878574</identifier><language>eng</language><publisher>England</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; Humans ; Induction Chemotherapy ; Psoriasis - drug therapy ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Clinical and experimental dermatology, 2024-02, Vol.49 (3), p.272-273</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c247t-536e69cf260c1f5037169a7880efbd9c65b8b1ac215aa25c53af4eb012841cd33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37878574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abbad-Jaime de Aragón, Carlota</creatorcontrib><creatorcontrib>Berna-Rico, Emilio</creatorcontrib><creatorcontrib>Goas, Almudena</creatorcontrib><creatorcontrib>Pérez-Bootello, Javier</creatorcontrib><creatorcontrib>Ballester-Martinez, María Asunción</creatorcontrib><creatorcontrib>Jaén, Pedro</creatorcontrib><creatorcontrib>Blauvelt, Andrew</creatorcontrib><creatorcontrib>González-Cantero, Álvaro</creatorcontrib><title>Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis</title><title>Clinical and experimental dermatology</title><addtitle>Clin Exp Dermatol</addtitle><description>This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of &lt; 1.</description><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Humans</subject><subject>Induction Chemotherapy</subject><subject>Psoriasis - drug therapy</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0307-6938</issn><issn>1365-2230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo1kMtKxDAUQIMoOo6u3EuWgsTJo3l0KeILBtyM65ImqRNtm9qkDOPX-C1-mRFnVpd7OfcsDgAXBN8QXLKFcXbRttoyQQ7AjDDBEaUMH4IZZlgiUTJ1Ak5jfMeYMCL5MThhUknFZTEDfuVbO-oP_zV1uka-t5NJPvQwrd2ohy1sQtuGjbOw3v5864h652zebIi-f4O-h4NO3vUpwo1Pa9hlHUoBdcHm_-TgEMPodfTxDBw1uo3ufDfn4PXhfnX3hJYvj893t0tkaCET4kw4UZqGCmxIwzGTRJRaKoVdU9vSCF6rmmhDCdeacsOZbgpXY0JVQYxlbA6u_r3DGD4nF1PV-WhcLtS7MMWKKkUZLbAsM3r9j5oxxDi6phpG3-lxWxFc_bWtcttq1zbTlzvxVHf5vmf3Mdkvrnx45Q</recordid><startdate>20240214</startdate><enddate>20240214</enddate><creator>Abbad-Jaime de Aragón, Carlota</creator><creator>Berna-Rico, Emilio</creator><creator>Goas, Almudena</creator><creator>Pérez-Bootello, Javier</creator><creator>Ballester-Martinez, María Asunción</creator><creator>Jaén, Pedro</creator><creator>Blauvelt, Andrew</creator><creator>González-Cantero, Álvaro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240214</creationdate><title>Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis</title><author>Abbad-Jaime de Aragón, Carlota ; Berna-Rico, Emilio ; Goas, Almudena ; Pérez-Bootello, Javier ; Ballester-Martinez, María Asunción ; Jaén, Pedro ; Blauvelt, Andrew ; González-Cantero, Álvaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c247t-536e69cf260c1f5037169a7880efbd9c65b8b1ac215aa25c53af4eb012841cd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Humans</topic><topic>Induction Chemotherapy</topic><topic>Psoriasis - drug therapy</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abbad-Jaime de Aragón, Carlota</creatorcontrib><creatorcontrib>Berna-Rico, Emilio</creatorcontrib><creatorcontrib>Goas, Almudena</creatorcontrib><creatorcontrib>Pérez-Bootello, Javier</creatorcontrib><creatorcontrib>Ballester-Martinez, María Asunción</creatorcontrib><creatorcontrib>Jaén, Pedro</creatorcontrib><creatorcontrib>Blauvelt, Andrew</creatorcontrib><creatorcontrib>González-Cantero, Álvaro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abbad-Jaime de Aragón, Carlota</au><au>Berna-Rico, Emilio</au><au>Goas, Almudena</au><au>Pérez-Bootello, Javier</au><au>Ballester-Martinez, María Asunción</au><au>Jaén, Pedro</au><au>Blauvelt, Andrew</au><au>González-Cantero, Álvaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis</atitle><jtitle>Clinical and experimental dermatology</jtitle><addtitle>Clin Exp Dermatol</addtitle><date>2024-02-14</date><risdate>2024</risdate><volume>49</volume><issue>3</issue><spage>272</spage><epage>273</epage><pages>272-273</pages><issn>0307-6938</issn><eissn>1365-2230</eissn><abstract>This retrospective real-world evidence study investigates the efficacy of as-needed dosing of tildrakizumab in patients with mild-to-moderate psoriasis. Patients received the first three standard doses of tildrakizumab, and thereafter used as-needed dosing over the course of 2.5 years, rather than the approved interval of every 12 weeks. Adequate disease control was achieved, reaching a mean Psoriasis Area and Severity Index at the end of follow-up of &lt; 1.</abstract><cop>England</cop><pmid>37878574</pmid><doi>10.1093/ced/llad361</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0307-6938
ispartof Clinical and experimental dermatology, 2024-02, Vol.49 (3), p.272-273
issn 0307-6938
1365-2230
language eng
recordid cdi_proquest_miscellaneous_2882324079
source Oxford Journals Online
subjects Antibodies, Monoclonal, Humanized - therapeutic use
Humans
Induction Chemotherapy
Psoriasis - drug therapy
Severity of Illness Index
Treatment Outcome
title Tildrakizumab-induction therapy followed by as-needed dosing in patients with mild-to-moderate psoriasis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T12%3A13%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tildrakizumab-induction%20therapy%20followed%20by%C2%A0as-needed%20dosing%20in%20patients%20with%20mild-to-moderate%20psoriasis&rft.jtitle=Clinical%20and%20experimental%20dermatology&rft.au=Abbad-Jaime%20de%20Arag%C3%B3n,%20Carlota&rft.date=2024-02-14&rft.volume=49&rft.issue=3&rft.spage=272&rft.epage=273&rft.pages=272-273&rft.issn=0307-6938&rft.eissn=1365-2230&rft_id=info:doi/10.1093/ced/llad361&rft_dat=%3Cproquest_cross%3E2882324079%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c247t-536e69cf260c1f5037169a7880efbd9c65b8b1ac215aa25c53af4eb012841cd33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2882324079&rft_id=info:pmid/37878574&rfr_iscdi=true